Kantarjian H - Search Results

1

Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1.

Mill CP, Fiskus W, Das K, Davis JA, Birdwell CE, Kadia TM, DiNardo CD, Daver N, Takahashi K, Sasaki K, McGeehan GM, Ruan X, Su X, Loghavi S, Kantarjian H, Bhalla KN. Mill CP, et al. Among authors: kantarjian h. Leukemia. 2023 Jun;37(6):1336-1348. doi: 10.1038/s41375-023-01882-4. Epub 2023 Mar 28. Leukemia. 2023. PMID: 36977823 Free PMC article.

2

Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16.

Marlton P, Keating M, Kantarjian H, Pierce S, O'Brien S, Freireich EJ, Estey E. Marlton P, et al. Among authors: kantarjian h. Leukemia. 1995 Jun;9(6):965-71. Leukemia. 1995. PMID: 7596186

3

Expression pattern of WT1 and GATA-1 in AML with chromosome 16q22 abnormalities.

Patmasiriwat P, Fraizer GC, Claxton D, Kantarjian H, Saunders GF. Patmasiriwat P, et al. Among authors: kantarjian h. Leukemia. 1996 Jul;10(7):1127-33. Leukemia. 1996. PMID: 8683991

4

Treatment of newly diagnosed AML, RAEB-t or RAEB with lisofylline or placebo in addition to chemotherapy.

Estey EH, Thall PF, Reed P, Kantarjian H, Beran M, Pierce S, Keating MJ. Estey EH, et al. Among authors: kantarjian h. Leukemia. 1999 Jun;13(6):850-4. doi: 10.1038/sj.leu.2401443. Leukemia. 1999. PMID: 10360371 Clinical Trial.

5

Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing.

Sarriera JE, Albitar M, Estrov Z, Gidel C, Aboul-Nasr R, Manshouri T, Kornblau S, Chang KS, Kantarjian H, Estey E. Sarriera JE, et al. Among authors: kantarjian h. Leukemia. 2001 Jan;15(1):57-61. doi: 10.1038/sj.leu.2401951. Leukemia. 2001. PMID: 11243400

6

Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA.

Jilani I, Estey E, Manshuri T, Caligiuri M, Keating M, Giles F, Thomas D, Kantarjian H, Albitar M. Jilani I, et al. Among authors: kantarjian h. Leukemia. 2003 Jan;17(1):114-9. doi: 10.1038/sj.leu.2402743. Leukemia. 2003. PMID: 12529667

7

Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML.

Estey E, Giles F, Cortes J, Beran M, Verstovsek S, Garcia-Manero G, Faderl S, Kantarjian H. Estey E, et al. Among authors: kantarjian h. Leuk Res. 2003 Jun;27(6):475-9. doi: 10.1016/s0145-2126(03)00031-6. Leuk Res. 2003. PMID: 12648505

8

A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.

Giles FJ, Cortes JE, Kantarjian HM, O'Brien SM, Estey E, Beran M. Giles FJ, et al. Leuk Res. 2004 Apr;28(4):353-7. doi: 10.1016/j.leukres.2003.08.013. Leuk Res. 2004. PMID: 15109534 Clinical Trial.

9

C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome.

Tsao AS, Kantarjian H, Thomas D, Giles F, Cortes J, Garcia-Manero G, Huh Y, Yang Y, Shen Y, Albitar M, Estey E. Tsao AS, et al. Among authors: kantarjian h. Leuk Res. 2004 Apr;28(4):373-8. doi: 10.1016/j.leukres.2003.09.008. Leuk Res. 2004. PMID: 15109537

10

FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype.

Beran M, Luthra R, Kantarjian H, Estey E. Beran M, et al. Among authors: kantarjian h. Leuk Res. 2004 Jun;28(6):547-50. doi: 10.1016/j.leukres.2003.09.016. Leuk Res. 2004. PMID: 15120929

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,549 results

Search Page

Filters